摘要
截短侧耳类抗菌药物泰妙菌素和沃尼妙林是兽医专用药。随着病原菌对现有药物的耐药性在全球范围蔓延,现在兴起了开发新的截短侧耳衍生物用于治疗人类细菌感染。瑞他帕林(Rapamulin)是第一个用于人医的截短侧耳类药物,2007年被批准用于由金黄色葡萄球菌(Staphylococcus aureus)和酿脓葡萄球菌(Staphylococcus pyogenes)引起的皮肤感染。截短侧耳衍生物在人医上的开发应用使其耐药机制成为国际上的研究热点。本文就截短侧耳类药物耐药机制及其传播机理的研究进展进行综述。
Pleuromutilin antibiotics tiamulin and valnemulin have been exclusively used in veterinary medicine.In recent years,due to the global spread of antibiotic resistance,the renewed development and application of novel pleuromutilin derivatives for human use have already become a hotspot.Ratapamulin is the first drug in the new class of pleuromutilin antibiotics to be approved for human use.It was approved in 2007 for the treatment of bacterial skin infections caused by Staphylococcus aureus.The pleuromutilin resistance mechanism has already become one of the research hotspots.In this paper,we made a brief overview of the resistance and transfer mechanisms for the pleuromutilin antibiotics.
出处
《畜牧与兽医》
北大核心
2017年第2期107-111,共5页
Animal Husbandry & Veterinary Medicine
基金
国家自然科学基金(31302145)
关键词
截短侧耳类
耐药性
传播
泰妙菌素
沃尼妙林
pleuromutilins
antibiotic resistance
transmission
tiamulin
valnemulin
